活血通络汤对下肢深静脉血栓形成相关因素的干预性研究
|
摘要
本文运用中医传统理论,根据导师许建安教授长期治疗下肢深静脉血栓形成丰富的临床经验,应用活血通络汤进行实验研究,探索其在血栓形成方面的预防作用及其作用机制。
近年来,下肢深静脉血栓形成病理机制的理论进展认为:炎症与血栓形成密切相关以及内皮功能损害在血栓形成中占有重要地位。血流缓慢、血液成分异常和血管损伤是静脉血栓形成三大发病原因,我们将其作为相关因素进行研究,通过动物实验,设立空白对照组,以复方丹参片、阿司匹林作为对照,分成活血通络汤高、中、低剂量组,建立血瘀证大鼠模型、创伤性深静脉损伤模型、HUVECs缺氧-复氧(I/R)模型,系统地探讨了中药对血管内皮显微结构和内皮细胞功能的影响,研究了深静脉血栓形成与内皮细胞表达细胞粘附分子—CD54表达、中性粒细胞粘附关系,进行了中药对静脉血栓形成后血液流变学、凝血功能和血管壁炎性细胞干预的研究,论证了炎症与血栓形成的关系。
实验结果表明:各剂量组对创伤性大鼠深静脉血管损伤均具有保护作用,含药血清中、高剂量组干预内皮细胞CD54分子表达数与缺氧组有明显区别,统计学处理有显著差异(P＜0.05),提示活血通络汤可以改善内皮细胞在缺氧条件下的细胞粘附性。活血通络汤高剂量组可见中性粒细胞与血管内皮细胞的粘附率显著降低,与缺氧组有明显区别,统计学处理有显著差异(P＜0.05),表明活血通络汤可能是通过影响两种细胞之间的粘附来发挥其抗血栓作用。活血通络汤具有显著抑制血栓形成、抑制血小板粘附、聚集,降低血液粘度的作用,降低足跖肿胀容积及肿胀率,抑制CD54表达,抑制炎性细胞的浸润,保护血管内皮细胞功能等作用。
可以得出结论:活血通络汤防治深静脉血栓形成不是单一作用,而是具有多种综合调节作用,对血栓形成的每个因素都能发挥作用,从分子生物学角度分析,活血通络汤对深静脉血栓形成相关因素的干预机制主要表现在对血管内皮细胞的保护方面,对血栓形成复杂的发病机理特点具有良好的针对性和科学性,本研究对防治DVT会带来良好的社会效益和经济效益。
By use of theory of traditional Chinese medicine(TCM) and combination with copious clinical experience of Prof. Xu Jian-an on treating deep venous thrombosis, we explored the prophylactic effect and mechanism of action of Huo Xue Tong Luo broth.
It is believed that lower limbs deep venous thrombosis is stronger relation to inflammation and endothelium dysfunction which play roles in thrombosis by recently developed theory of mechanism of deep venous thrombosis. The correlation factor includes Three kind of main etiological factor: slow bloodstream,abnormal blood constituents, vascular injury.It is systematically discussed that Huo Xue Tong Luo broth was able to influence on endothelium structure and function. We have been initially discussed that expression of CD54 of endothelial cells and inflammatory cells of vascular wall those were association with venous thrombosis. We studied on effect of Huo Xue Tong Luo broth on interventional mechanism of hemorheology, thromboxane function inflammatory cells in rats with deep venous thrombosis. We demonstrated the relationship between inflammation and thrombosis.
Huo Xue Tong Luo Broth can lighten traumatic occlusion deep vein injury of rats. Middle and/or high dose blood serum containing broth can lower neutrophil adhesion rate and platelet aggregation rate(P<0.05).It is showed that the mechanism of Huo Xue Tong Luo broth was association with inhibiting thrombosis, platelet adhesion reaction and aggregation, degrading blood viscidity, decreasing voix pedis voix pedis swelling volume and ratio, inhibiting expression of CD54 and inflammatory cell infiltrating, protecting vascular endothelial cell function.
We conclude that Huo Xue Tong Luo broth has multiply synthetic adjusting therapeutic action on deep venous thrombosis. We think it possesses well direct and scientific siginificance to complicated pathogenesis about thrombosis.
近年来,下肢深静脉血栓形成病理机制的理论进展认为:炎症与血栓形成密切相关以及内皮功能损害在血栓形成中占有重要地位。血流缓慢、血液成分异常和血管损伤是静脉血栓形成三大发病原因,我们将其作为相关因素进行研究,通过动物实验,设立空白对照组,以复方丹参片、阿司匹林作为对照,分成活血通络汤高、中、低剂量组,建立血瘀证大鼠模型、创伤性深静脉损伤模型、HUVECs缺氧-复氧(I/R)模型,系统地探讨了中药对血管内皮显微结构和内皮细胞功能的影响,研究了深静脉血栓形成与内皮细胞表达细胞粘附分子—CD54表达、中性粒细胞粘附关系,进行了中药对静脉血栓形成后血液流变学、凝血功能和血管壁炎性细胞干预的研究,论证了炎症与血栓形成的关系。
实验结果表明:各剂量组对创伤性大鼠深静脉血管损伤均具有保护作用,含药血清中、高剂量组干预内皮细胞CD54分子表达数与缺氧组有明显区别,统计学处理有显著差异(P＜0.05),提示活血通络汤可以改善内皮细胞在缺氧条件下的细胞粘附性。活血通络汤高剂量组可见中性粒细胞与血管内皮细胞的粘附率显著降低,与缺氧组有明显区别,统计学处理有显著差异(P＜0.05),表明活血通络汤可能是通过影响两种细胞之间的粘附来发挥其抗血栓作用。活血通络汤具有显著抑制血栓形成、抑制血小板粘附、聚集,降低血液粘度的作用,降低足跖肿胀容积及肿胀率,抑制CD54表达,抑制炎性细胞的浸润,保护血管内皮细胞功能等作用。
可以得出结论:活血通络汤防治深静脉血栓形成不是单一作用,而是具有多种综合调节作用,对血栓形成的每个因素都能发挥作用,从分子生物学角度分析,活血通络汤对深静脉血栓形成相关因素的干预机制主要表现在对血管内皮细胞的保护方面,对血栓形成复杂的发病机理特点具有良好的针对性和科学性,本研究对防治DVT会带来良好的社会效益和经济效益。
By use of theory of traditional Chinese medicine(TCM) and combination with copious clinical experience of Prof. Xu Jian-an on treating deep venous thrombosis, we explored the prophylactic effect and mechanism of action of Huo Xue Tong Luo broth.
It is believed that lower limbs deep venous thrombosis is stronger relation to inflammation and endothelium dysfunction which play roles in thrombosis by recently developed theory of mechanism of deep venous thrombosis. The correlation factor includes Three kind of main etiological factor: slow bloodstream,abnormal blood constituents, vascular injury.It is systematically discussed that Huo Xue Tong Luo broth was able to influence on endothelium structure and function. We have been initially discussed that expression of CD54 of endothelial cells and inflammatory cells of vascular wall those were association with venous thrombosis. We studied on effect of Huo Xue Tong Luo broth on interventional mechanism of hemorheology, thromboxane function inflammatory cells in rats with deep venous thrombosis. We demonstrated the relationship between inflammation and thrombosis.
Huo Xue Tong Luo Broth can lighten traumatic occlusion deep vein injury of rats. Middle and/or high dose blood serum containing broth can lower neutrophil adhesion rate and platelet aggregation rate(P<0.05).It is showed that the mechanism of Huo Xue Tong Luo broth was association with inhibiting thrombosis, platelet adhesion reaction and aggregation, degrading blood viscidity, decreasing voix pedis voix pedis swelling volume and ratio, inhibiting expression of CD54 and inflammatory cell infiltrating, protecting vascular endothelial cell function.
We conclude that Huo Xue Tong Luo broth has multiply synthetic adjusting therapeutic action on deep venous thrombosis. We think it possesses well direct and scientific siginificance to complicated pathogenesis about thrombosis.
引文
[1]Boeealon H.Exploration vascularies.1st ed.Paris:Masson,1991,281-311.
[2]Flinn WR,Sandager GP,Silva MB Jr,et al.Prospective surveillance for perioperative venous thrombosis experience in 2643 patients[J].Arch Surg.1996 May,131(5):472-80.
[3]Ferrari E,Baudouy M,Cerhoni P.Clinical epidemiology of venous thrombolic disease.Results of a French Mulrticentre Registry[J].Eur Heart J,1997,18(4):685.
[4]Macis G,Salcuni M,Cotroneo AR,et al.Pulmonary thromboembolism and diagnostic imaging:integration of techniques and methods[J].Radiol Med Torino,1996,92:63.
[5]Eftychiou V.Clinical diagnosis and maganement of the patient with deep venous thromboembolism and pulmon embolism[J].Nurse Pract,1995,21:50.
[6]Lindner D,Edwards J,Phinncy E,et al.Long-term hermodynamic and clinical sequelae of lower extremity deep vein thrombosis[J].J Vasc Surg 1986,4(5):436.
[7]Prandoni P,Lensing AW,Buller HR,et al.A simple ultrasound approach for detection of recurrent proximal vein thrombosis[J].Circulation,1993,88(part1):1730.
[8]Standness DE,Langlois Y,Cramer M,et al.Long-term sequelae of acute venous thrombosis[J].JAMA 1983,250(10):1289.
[9]Coon WW.Epidemiology of venous thromboembolism and other venous disease in the Tecumseh Community[J].Health Study Circulation 1973,48(4):839.
[10]Robert B.Rutherford,M.D.Rutherford Vascular Surgery(fifth edition)[M]影印版.北京:人民卫生出版社,2002,1920 58.
[11]张卉,贺蓉,贺石林.炎症与血栓形成[J].中华医学杂志,2004,84(9):784.
[12]Weksler BB,Ley CW,Jaffe EA.Stimulation of endothelial cell prostacyclin production by thrombin,trypsin and the ionophore A23187[J].J Clin Invest,1978,62(5):923-930.
[13]Prescott SM,Zimmerman GA,McIntyre IM.Human endothelial cells in culture produce platelet activating factor(1-alkyl-2-acetyl-sn-60 glycero-3-phosphocholine) when stimulated with thrombin[J].Proc Natl Acad Sci USA,1984,81(11):3534-3538.
[14]Lorant DE,Patel KDA,Mclntyre TM,et al.Coexpression of GMP-140 and platelet activating factor by endothelium stimulated by histamine and thrombin:A juxtacrine system for adhesion and activation of neurophils[J].J Cell Biol,1991,115(1):223-231.
[15]Carlos TM,Harlan JM.Leukocyte-endothelial adhesion molecules[J].Blood,1994,84(7):2068-2101.
[16]Wakefield TW,Strieter RM,Monreal L,et al.Venous thrombosis associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules[J].Arterioscle Thromb Vasc Biol,1995,15(2):258-268.
[17]Baggiolini M,Dewald B,Moser B.Interleukin-8 and related chemotactic cytokines CXC and CC chemokines[J].Adv Immunol.1994,55:97-179.
[18]Downing LJ,Wakefield TW,Strieter RM,et al.Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis[J].J Vasc Surg,1997,25(5):816-827.
[19]李家增,贺石林.血栓形成与临床医学[M].长沙:湖南科学技术出版社,1991.
[20]李仪奎,姜名瑛.中药药理学[M].北京:中国中医药出版社,1992,48-144.
[21]郁琴,宋后燕.水蛭素在深静脉血栓治疗中的作用[J].中国心血管病研究杂志,2005,3(5):392-394.
[22]潘丽华.生三七粉降低血浆凝血固子[J].中国新药与临床杂志,2000,19(4):331-332.
[23]付伟.大剂量黄芪注射治疗糖尿病肾病性肾功能衰竭的临床观察[J].中国中医药信息杂志,2000,11(7):57.
[24]林爱华,李予蓉.黄芪对小鼠免疫功能的影响[J].第四军医大学学报,2003,24(8):2.
[1]Kakkar VV.Pathophysiologic characteristics of venous thrombosis[J].Am J Surg 1985,50(4A):1-6.
[2]Comerota AJ,Stewart GJ,White JV.Combined dihydroergotamine and heparin prophylaxis of postoperative deep vein thrombosis:proposed mechanism of action[J].Am J Surg.1985,150(4A):39-44.
[3]张延龄.静脉血栓形成的防治近况[J].国外医学外科学分册,1991,(2):70.
[4]Dahlback B.Inherited Thrombophilia:resistance to activated protein C as a pathogenic factor of venous thromboembolism[J].Blood,1985,85:607.
[5]Dahlbaek B,Hildebrand B.Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a poperty of factor Ⅴ[J].proc Natl Acad Sci USA,1994,91:1396.
[6]Bertina RM,Koeleman BPC,Koster T,et al.Mutation in blood coagulation factor Ⅴ associated with resisance to activated protein C[J].Nature,1994,369:64.
[7]Voorbeg J,Roclse J,Koopman R,et al.Association of idiopathic thromboembolism with single point-mutation at Agr 506 of factor Ⅴ[J].Lancet,1994,343:1535.
[8]王钦红.抗活化蛋白C是引起静脉血栓形成的一个重要原因[J].中华血液学杂志,1996,(9):499.
[9]储海燕,诸江,王鸿利,等.上海地区深静脉血栓形成患者抗活化蛋白C及FV Leiden突变的初 步调查[J].中华血液学杂志,1996,(9):462.
[10]Sevitts,Grllaghcr N:Venous thrombosis and pulmonary embolism:A clinico-pathological study in injured and burned victims.Br J Surg 1961,48:475.
[11]Thomas DP,Merton RE,Wood RD,et al.The relationship between vessel wall injury and venous thrombosis:an experimential study.Br Haematol 1985,59(3):449.
[12]Robert B.Rutherford,M.D.Rutherford Vascular Surgery(fifth edition)[M]影印版.北京:人民卫生出版社,2002,1920 58.
[13]冯友贤.血管外科学[M].第二版.上海:上海科学技术出版社,1992,195-533.
[14]Carter Cb,Anderson FA,Wheeler HB:Epidemiology and patholphysiology of venous thromboembolism.In Hull RD,Raskob GE,Pinco GF(cds):Venous Thromboembolism:An Evidence-based Atlas.Armonk,NY,Futura Publishing Company,1996,p3.
[15]Luscher TB,Barton M.Biology of the endothelium[J].Clin Cardiol,1997,20(suppl Ⅰ):Ⅱ3-10.
[16]Celermajer DS.Endothelial dysfunction:Do it matters? Is it reversible?[J]J Am Cardiol 1997,30:325-333.
[17]Hunt BJ,Jurd KM.Endothelial cell activation:a central pathophysiologica process[J].B M J,1998,316:1328-1329.
[18]Adams DH,Shaw S.Leucocyte-endothelial interactions and regulation of leucocyte migrati -on[J].Lancet 1994;343:831-6.
[19]Bach FH,Robson SC,Winkler H,et al.Barriers to xenotransplantation[J].Nature Medicine 1995,1:869-73.
[20]张卉,贺蓉,贺石林.炎症与血栓形成[J].中华医学杂志,2004,84(9):784.
[21]Weksler BB,Ley CW,Jaffe EA.Stimulation of endothelial cell prostacyclin production by thrombin,trypsin and the ionophore A23187[J].J Clin Invest,1978,62(5):923-930.
[22]Prescott SM,Zimmerman GA,McIntyre IM.Human endothelial cells in culture produce platelet activating factor(1-alkyl-2-acetyl-sn-60 glycero-3-phosphocholine) when stimulated with thrombin[J].Proc Natl Acad Sci USA,1984,81(11):3534-3538.
[23]Lorant DE,Patel KDA,Mclntyre TM,et al.Coexpression of GMP-140 and platelet activating factor by endothelium stimulated by histamine and thrombin:A juxtacrine system for adhesion and activation of neurophils[J].J Cell Biol,1991,115(1):223-231.
[24]Carlos TM,Harlan JM.Leukocyte-endothelial adhesion molecules[J].Blood,1994,84(7):2068-2101.
[25]Wakefield TW,Strieter RM,Monreal L,et al.Venous thrombosis associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules[J].Arterioscle Thromb Vasc Biol,1995,15(2):258-268.
[26]Baggiolini M,Dewald B,Moser B.Interleukin-8 and related chemotactic cytokines CXC and CC chemokines[J].Adv Immunol.1994,55:97-179.
[27]Downing LJ,Wakefield TW,Strieter RM,et al.Anti-P-selectin antibody decreases inflamm -ation and thrombus formation in venous thrombosis[J].J Vasc Surg,1997,25(5):816-827.
[28]刘政,侯玉芬,周涛,林海青,等.消栓通脉颗粒剂对深静脉血栓形成模型大鼠血浆t-PA、PAI的影响[J].中医药学刊,第24卷第10期2006,24(10):1846-1848.
[29]Rice GE,Munro JM,Bevilacqua MP.Inducible cell adhesion molecule 110(ICAM-1)is an endothelial receptor for lymphocytes A CD11/CD18-independent adhesion mechanism.ExpMed,1990,171(4):1369.
[30]梁春,吴宗贵,仲人前,等.普伐他汀抑制ox-LDL诱导的人外周血单核细胞CD11b表达及与内皮的粘附.中国药理学通报,1999,15(3):249.
[31]Albelds SM,Smith CM,Ward PA,et al.Adhesionmolecules and inflammatory injury[J].FASEB J,1994,8(2):504-512.
[32]宋晓燕.流动剪切力对鼠脑微血管内皮细胞ICAM-1表达的影响[J].生理学报,2001,53(1):13.
[33]卿晨,丁健.黏附分子ICAM-1表达家族在调节细胞凋亡中的作用[J].国外医学·分子生物学分册,2000,22(1):17.
[34]Smith MD,Slavotinek J,Au V,et al.Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression.Rheumatology,2001,40:965-977.
[35]顾光,陈海英,魏平,等.CD54与强直性脊柱炎相关性的临床研究[J].河北医药,2005,27(10):729-730.
[36]邓耀祖,曲伸.医学分子细胞生物学[M].北京:科学出版社,2002;494.
[37]朱彪,薛张纲,蒋豪.粘附分子和心肌缺血再灌注损伤的新进展[J].国外医学·麻醉血与复苏分册,2003;24(3):167-170.
[38]张轶,刘中民.细胞间粘附分子-1与心肌缺血再灌注损伤的关系[J].国外医学·心血管分册,2001;28(5):259-261.
[39]王洪超,周童亮,阎景波,等.内皮细胞缺血再灌注损伤中粒细胞和ICAM-1作用的实验研究[J].中日友好医院学报,2002;16(1):24-27.
[40]郑立新,周晓红,安琪等.PDTC对缺氧/再给氧时血管内皮细胞ICAM-1,VCAM-1表达的作用[J].中国胸心血管外科临床杂志,2004;n(1):53-55.
[41]李家增,贺石林.血栓形成与临床医学[M].长沙:湖南科学技术出版社,1991.
[42]李仪奎,姜名瑛.中药药理学[M].北京:中国中医药出版社,1992,48-144.
[43]张旭,张超英,王文,等.丹参药物血清对HUVEC黏附分子表达及胞内Ca~(2+)的影响[J].南京中医药大学学报,2007,23(1):30-32.
[44]平井爱山.活血化瘀药牡丹皮及其有效成分对芍药酚对血小板的抑制作用及其机理[J].国外医学中医中药分册,1984;(1):53.
[45]李学林,李威,陈国华,等.牛膝活血作用的实验研究[J].中医研究,1990;3(2):27-29.
[46]陈学东,田道法,刘红萍,等.地龙煎液对人出血、凝血时间的影响[J].湖南中学院学报,2003,23(2):10-11.
[47]马恩龙,李艳春,曹颖林,等·溶栓1号抗血小板聚集及抗血栓形成作用[J]·沈阳药科大学学报,2001,18(5):370-372.
[48]马培志,邵凤民.蚯蚓提取物对原发性肾病综合症患者凝血系统的影响[J].中国中西医结合肾病杂志,2002,3(9):528-529.
[49]韩正雪,赖光强,张维,等.地龙水煎剂对血小板聚集的影响[J].中外健康文摘·临床医药版.2008,5(4):25-26.
[50]王秀华,刘爱东,徐彩云.鸡血藤抗血栓形成作用的研究,长春中医学院学报,2005,12(4):41.
[51]陈少鹏,韩雅莉,郭桅,等.少棘蜈蚣纤溶活性蛋白的抗血栓作用[J].中药药理学通报,2007,23(8):1088.
[52]石宏志,高南南,李勇枝,等.泽兰有效部分对血小板聚集和血栓形成的影响[J].中草药.2003,34(10):923-926
[53]Shi H Z,Gao N N,Li Y Z,et al.Effects of active fractions from Lycopus lucidusL.F04 on erythrocyterheology[J].Space Med Med Eng(航天医学与医学工程),2002,15(5):331-334.
[54]陶晋舆,吕环,张秋菊,等.泽泻抗动脉粥样硬化作用系列研究(二)[J].北京中医学院学报,1991,14(6):51.
[55]刘崇铭,王敏,梁力春.淫羊藿黄酮对脑血流和脑缺血的作用[J].沈阳药科大学学报,1995.12(3):192-194.
[56]常德有,董福慧.骨碎补的研究概况[J].吉林中医药,2006,26(6):61-62.
[57]中华人民共和国卫生部药典委员会.中华人民共和国药典(一部)[M].北京:人民卫生出版社,1995:284.
[58]江苏新医学院.中药大辞典(下册)[M],上海:上海科学技术出版社,1997:2243.
[59]王树梓,边全禄.鹿蹄草扩张血管作用的实验研究[J].陕西中医.1989,10(10):473.
[60]郑振源,周述芳,郭敏,等.鹿蹄草对小鼠组织血流量与血浆环核昔酸含量的影响[J].中药通报,1956;11(3):52-52.
[61]庄斐尔.鹿蹄草对心肌营养性血流的影响[J].中药通报,1987;6(6):31.
[62]陈长勋.中药药理学[M].上海科学技术出版社,2006,165.
[63]Marcel Levi,Janine D?rffler-Melly,Gerhard J.Johnson,et al.Usefulness and Limitations of Animal Models of Venous Thrombosis[J].Thromb Haemost,2001,86:1331
[64]Reyers I,Mussoni L,Donati MB,et al.Failure of aspirin at different doses to modify experimental thrombosis in rats[J].Thromb Res,1980,18(5):669.
[65]Myers DD,Hawley AE,Farris DM,et al.P-selectin and leukocyte microparticles are associated with venous thrombogenesis[J].J Vasc Surg 2003,38:1075.
[66]王敏,王骏,邵明远,等.链霉菌产生的新型纤溶酶的纤溶性质和溶栓作用[J].药学学报,1998, 33(7):481.
[67]刘广芬,王晴川,许云禄.蕲蛇酶对动物实验性血栓的防栓和溶栓作用[J].蛇志,1997,9(3):2.
[68]何晓凡,熊石龙,刘发益,等.国产抗凝血酶Ⅲ对实验性静脉血栓形成的预防作用观察[J].血栓与止血,2002,8(1):5
[69]Rhodes JM,Cho JS,Gloviczki P,et al.Thrombolysis for experimental deep venous thrombosis maintain valvular competence and vasoreactivity[J].J Vasc Surg,2000,31:1193.
[70]戎建杰,伍波,何礼荣,等.导管直接溶栓治疗犬股静脉急性深静脉血栓后静脉壁形态学的变化[J].苏州大学学报(医学版),2004,24(2):169.
[71]王辉,王岭,陈江浩,等.腔内超声溶栓治疗犬外周血管血栓形成[J].第四军医大学学报,2003,24(10):870.
[72]周为民,李晓强,余朝文,等.血栓消融、溶栓和取栓对犬股静脉壁形态学影响的研究[J].中国普通外科杂志,2003,18(4):214.
[73]李晓强,杨明,余朝文,等.尿激酶对兔急性血栓后静脉壁形态变化的影响[J].中华医学杂志,2002,82(8):568
[74]季顺东,刘晓健,张荣军,等.99Tcm-抗血栓成分单克隆抗体对动物血栓的放免显像研究[J].苏州医学院报,2000,20(1):4
[75]安锐,张凯军,黄韬,等.99Tcm-SZ-51用于犬静脉血栓模型放射免疫显像的研究[J].临床心血管病杂志,2000,16(12):554
[76]Knight LC,Maurer Ah,Ammar I A,et al.Tc-99m antifibrin fragment for imaging venous thrombi:Evaluation in a canine model[J].Radiology,1989,173:163
[77]杨军,屈立志,杨霄,等.复方丹参片片对深静脉血栓形成纤溶功能的实验观察[J].中药新药与临床药理,2003,14(1):32
[78]豀忠人.激素剂的致瘀血作用和桂枝茯苓丸的祛瘀血作用[J].国外医学·中医中药分册,1985,7(6):4.
[79]覃建民,李增晞,石山.实验性体内血栓形成测定仪的研制和使用[J].中国药理学通报,1992,8(2):236.
[80]王健.静脉血栓形成动物模型的病理学研究[J].蚌埠医学院学报,2003,28(1):7.
[81]李晓强,余朝文,杨明,等.顺行和逆行取栓对静脉瓣膜及血管壁的影响[J].蚌埠医学院学报,2000,25(5):313.
[82]徐晖,朱妙章,裴建民,等.大鼠实验性血栓模型的建立及其评价[J]中国应用生理学杂志,1997,13(1):89-90.
[83]胡敏,赵宏斌,王兵,等.创伤后兔肢体深静脉血栓形成的影响因素[J].中国临床康复,2005,9(10):156-157.
[84]刘涛,卞慧敏,张蕊,等.改良三甲散活血化淤作用实验研究[J].实用中医药杂志,2003,19(10):508-509.
[85]邓祖跃,辛艳飞.番茄红素对高脂血症大鼠血凝及纤溶的影响[J].时珍国医国药,2007,18(1):88-89.
[86]李建林.纤溶系统与动脉血栓形成[J].中西医结合心脑血管病杂志,2006,4(12):1086-1087.
[87]刘伟,王洋,脉通胶囊对大鼠纤溶系统的影响[J].中医药学报,2005,33(2):31-32.
[88]王翠梅,曹红.冠状内皮细胞与心肌缺血再灌注损伤[J].国外医学.麻醉学与复苏分册,2004;25(2):114-117.
[1]Andrew DB,Gregory YHL.Venous thromboembolism.BMJ,2006,332:215-219.
[2]张伯根.下肢深静脉血栓形成治疗的几个问题[J].中华普通外科杂志,2006,21(2):81-83.
[3]Thomas WW,Robert MS,Carol AW,et al.Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules[J].Arteriosclerosis,Thrombosis,and Vascular Biology,1995,15:258-268.
[4]预防骨科大手术后深静脉血栓形成的专家建议-深静脉血栓形成预防座谈会纪要.中华骨科杂志,2005,25(10):636-640.
[5]Frits RR.Venous thrombosis:the role of genes,environment,and behavior[J].Hematology Am Soe Hematol Edue Program,2005:1-12.
[6]Colwell CW Jr,Hardwick ME.Natural History of Venous Thromboembolism.Techniques in Orthopaedics,2004,19:236-239.
[7]Geerts WH,Heit JA,Clagett GP,et al.Prevention of venous thromboembolism.Chest,2001,119:132S-175S.
[8]张强.外科手术后下肢深静脉血栓的预防与治疗[J].中国实用外科杂志,2001,21:263-265.
[9]吕厚山,徐斌.人工关节置换术后下肢深静脉血栓形成[J].中华骨科杂志,1999,19:155-160.
[10]Clagett GP,Anderson FA Jr,Geerts W,et al.Prevention of venous thromboembolism Chest.1998,114:531S -560S.
[11]Sharrock NE,Go G,Sculco TP,et al.Changes in circulatory indices of thrombosis and fihrinolysis during total knee arthroplasty performed under tourniquet[J].J Arthroplasty,1995,10:523-528.
[12]Sharrock NE,Go G,Harpel PC,et al.The John Charnley Award.Thrombogenesis during total hip arthroplasty[J].Clin Orthop RelatRes,1995,(319):16-27.
[13]Menzin J.Richner R.Huse D.et al.Prevention of deep vein thrombosis following total hip replacement surgery with enoxaparin versusunfractionated heparin:a pharm acoeconomic evaluation.Ann Pharmacother,1994,28:271-275.
[14]冯会祥.下肢深静脉血栓形成的诊断和治疗进展.医学理论与实践[M],2008,21(5):527-5-29.
[15]Tove yC,W yattS.Diagnosis,investigation,and management of deep vein thrombosis.Br Med J,2003;326:1180-1186.
[16]Yoshizako T,Sagimura K,Kawamitsu H,et al,Two-dimentional time of flight MR venography:assessment with detection of chronic deep venous thrombosis in combination transfer contrast[J].Comput Assisit Tomogr,1996,20(6):957-964.
[17]De Valois JC,vanSechaik CC,Verzijlbergen F,et al.Contrast venography:from gold standard to "golden backup"inclinically suspected deep vein thrombosis.Eur J Radiol,1990;11:131-137.
[18]Yoshida S,Akiba H,Tamakawa M,et al.Spiral CT venography of the lower extremities by injection via an arm vein in patients with leg swelling.Br JRadiol,2001;74:1013-1016.
[19]Fraser DGW,Moody AR,Morgan PS,et al.Diagnosis of lower limb deep venous thrombosis:a prospective blinded study of magnetic resonance direct thrombusi maging.AnnInternMed,2002;136:89-98.
[20]Westrich GH,Farrell C,Bono JV,et al.The incidence of venous thmmboembolism after total hip arthroplasty:a specific hypotensive epidural anesthesia protocol.J Arthroplasty.1999.14:456 -463.
[21]Prins MH,Hirsh J.A comparison of general anesthesia and regional anesthesia as a risk factor for deep venous thrombosis following hip surgery:a critical review.Thromb Haemost,1990,64:497-500.
[22]陈廖斌,顾洁夫,王华,等.足踝主、被动运动对下肢静脉回流的影响.中华骨科杂志,21(3):145-147.
[23]陈东峰,余楠生,卢伟杰,等.低分子肝素联合间歇充气加压预防人工关节置换术后下肢深静脉血栓形成.中华骨科杂志,2006,26(12):823-826.
[24]Silbersack Y,Taute BM,Hein W,et al.Prevention of deep vein thrombosis after total hip and knee replacement:low molecular-weight heparin in combination with intermittent pneumatic compression.J Bone Joint Surg(Br),2004,86:809- 812.
[25]Ryan MG,Westrich GH,Potter HG,et al.Effect of mechanical compressionon the prevalence of proximal deep venous thrombosis asassessed by magnetic resonance venography.J Bone Joint Surg(Am),2002,84:1998- 2004.
[26]杨刚,吕厚山,高健,等.低分子肝素预防人工髋、膝关节置换术后下肢深静脉血栓形成的研究.中华骨科杂志,2000,38(1):25-28.
[27]邱贵兴,杨庆铭,余楠生,等.低分子肝素预防髋、膝关节手术后下肢深静脉血栓形成的多中心研究.中华骨科杂志,2006,26(12):819-822.
[28]Kakkar W,Lawrence D.Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis:A prospective study.Am J Surg,1985,150:54-63.
[1]吕厚山,徐斌.人工关节置换术后下肢深静脉血栓形成[J].中华骨科杂志,1999,19(3):155.
[2]杨刚,吕厚山,高健,等.低分子肝素预防人工髋、膝关节置换术后下肢深静脉血栓形成的研究[J].中华外科杂志,2000,38(1):25-27.
[3]Brenkel J,Cook RE.Thromboprophylaxis in patients undergoing total hip replacement[J].Hosp Med,2003,64:281-287.
[4]Rmaswami G,Nicolaides AN.The cost- effectiveness of mechanical froms of DVT prophylax is in general surgery[J].Inter Angiol,1996,15(Supp1):21.
[5]Pitto RP,Hamer H,Fabiani R,et al Prophylaxis against fat and bone-marrow embolism during total hip arthroplasty reduces the incidence of postoperative deep vein thrombosis:a controlled,randomized clinical tria[J].J Bone Joint Surg Am,2002,84:39-48.
[6]李伟.髋关节置换术后深静脉血栓形成的中药防治[J].中国中医骨伤科杂志,1998,6(6):36-37.
[7]杨剑.活血利湿法治疗下肢深静脉血栓48例[J].中国现代医药杂志,2005,7(1):9.
[8]黄贵熙.中西医结合治疗下肢深静脉血栓形成31例[J].广西中医药,2003,26(2):29.
[9]高怀林.中西医结合治疗深静脉血栓形成临证探要[J].中医药学刊,2001,19(2):179.
[10]刘明伟,黄海滨,廖小波.活血化瘀方防治髋部骨折术后深静脉血栓[J].山东中医杂志,2002,21(182):722-723.
[11]李萍.奚九一教授治疗血栓性深静脉炎的经验介绍[J].贵阳中医学院学报,1999,21(1):14-16.
[12]朱之升,陈碧岚.中西医结合治疗髋部术后静脉血栓形成[J].浙江中西医结合杂志,2004,14(5):298-299.
[13]姜晓锐,陈联源.消肿活血汤配合低分子肝素钠预防髋部术后深静脉血栓形成65例[J].福建中医药,2006,37(5):27-28.
[14]袁临益,王文斌,冯米敬,等.丹参注射液预防下肢深静脉血栓形成临床观察[J].中医正骨,2006,18(4):6-8.
[15]梅汉尧,周永顶,索鹏,等.丹参预防人工全髋关节置换术后下肢深静脉血栓形成的研究[J].中国中医骨伤科杂志,2006,14(3):14-15.
[16]刘军,万豫尧,许树柴,等.益气活血法预防老年患者髋部术后下肢深静脉血栓形成[J].中国骨伤,2006,19(6):344-347.
[17]李文若,王海彬.川芎嗪、血液循环泵预防全髋置换术后深静脉血栓形成50例[J].新中医,2006,38(4):73.
[18]李玉吉,赵健雄.川芎嗪预防全髋关节置换术后深静脉血栓的疗效观察[J].甘肃中医,2006,19(5):19-20.
[19]饶耀剑,张俊,石福明,等.中药黄芪对全髋术后血液流变学影响[J].中医正骨,2007,19(10):4.
[20]赵代杰,曹飞.疏血通注射液预防下肢人工关节置换术后深静脉栓塞的应用[J].中国社区医师,2008,10(2):56.
[21]胡军林,冯国璋,戴号,等.中西医结合预防全膝关节置换术后深静脉栓塞[J].实用中西医结合临床,2004,4(5):30-31.
[22]沈计荣,蔡文辉,陈茂义,等.自拟活血化瘀汤防治人工膝关节术后深静脉血栓[J].黑龙江中医药.2002,6(6):17-18.
[23]沈映君.中药药理学[M].上海:上海科学技术出版社,1997.136.
[24]刘迅,童培建,章建华.活血通脉汤防治全膝关节置换术后深静脉血栓33例[J].浙江中医药大学学报.2006,30(5):495-496.
[25]闵文,沈计荣,闵正,等.活血Ⅰ号方预防人工髋、膝关节置换术后DVT发生的临床观察[J].中国中医骨伤科杂志,2007,15(12):25-27.
[26]刘光旺,陈茂义,周临东,等.化瘀消肿汤预防髋膝关节置换术后下肢深静脉血栓形成[J].国医论坛,2004,19(4):22.
[27]阮洪江,张世华.活血复元汤配合低分于肝素钠预防人工髋关节置换术后下肢深静脉血栓形成[J].中国骨伤,2005,18(12):719-721.
[28]罗剑虹,方明智,杨静.中西医结合预防髋部骨折术后深静脉血栓形成54例[J].江西中医药,2007,38(10):51.
[29]郁琴,宋后燕.水蛭素在深静脉血栓治疗中的作用[J].中国心血管病研究杂志,2005,3(5):392-394.
[30]潘丽华.生三七粉降低血浆凝血固子[J].中国新药与临床杂志,2000,19(4):331-332.
[31]付伟.大剂量黄芪注射治疗糖尿病肾病性肾功能衰竭的临床观察[J].中国中医药信息杂志,2000,11(7):57.
[32]林爱华,李予蓉.黄芪对小鼠免疫功能的影响[J].第四军医大学学报,2003,24(8):2.
[33]杨刚,吕厚山,高健,等.低分子肝素预防人工髋、膝关节置换术后下肢深静脉血栓形成的研究[J].中华外科杂志,2000,37(1):25-27.
[2]Flinn WR,Sandager GP,Silva MB Jr,et al.Prospective surveillance for perioperative venous thrombosis experience in 2643 patients[J].Arch Surg.1996 May,131(5):472-80.
[3]Ferrari E,Baudouy M,Cerhoni P.Clinical epidemiology of venous thrombolic disease.Results of a French Mulrticentre Registry[J].Eur Heart J,1997,18(4):685.
[4]Macis G,Salcuni M,Cotroneo AR,et al.Pulmonary thromboembolism and diagnostic imaging:integration of techniques and methods[J].Radiol Med Torino,1996,92:63.
[5]Eftychiou V.Clinical diagnosis and maganement of the patient with deep venous thromboembolism and pulmon embolism[J].Nurse Pract,1995,21:50.
[6]Lindner D,Edwards J,Phinncy E,et al.Long-term hermodynamic and clinical sequelae of lower extremity deep vein thrombosis[J].J Vasc Surg 1986,4(5):436.
[7]Prandoni P,Lensing AW,Buller HR,et al.A simple ultrasound approach for detection of recurrent proximal vein thrombosis[J].Circulation,1993,88(part1):1730.
[8]Standness DE,Langlois Y,Cramer M,et al.Long-term sequelae of acute venous thrombosis[J].JAMA 1983,250(10):1289.
[9]Coon WW.Epidemiology of venous thromboembolism and other venous disease in the Tecumseh Community[J].Health Study Circulation 1973,48(4):839.
[10]Robert B.Rutherford,M.D.Rutherford Vascular Surgery(fifth edition)[M]影印版.北京:人民卫生出版社,2002,1920 58.
[11]张卉,贺蓉,贺石林.炎症与血栓形成[J].中华医学杂志,2004,84(9):784.
[12]Weksler BB,Ley CW,Jaffe EA.Stimulation of endothelial cell prostacyclin production by thrombin,trypsin and the ionophore A23187[J].J Clin Invest,1978,62(5):923-930.
[13]Prescott SM,Zimmerman GA,McIntyre IM.Human endothelial cells in culture produce platelet activating factor(1-alkyl-2-acetyl-sn-60 glycero-3-phosphocholine) when stimulated with thrombin[J].Proc Natl Acad Sci USA,1984,81(11):3534-3538.
[14]Lorant DE,Patel KDA,Mclntyre TM,et al.Coexpression of GMP-140 and platelet activating factor by endothelium stimulated by histamine and thrombin:A juxtacrine system for adhesion and activation of neurophils[J].J Cell Biol,1991,115(1):223-231.
[15]Carlos TM,Harlan JM.Leukocyte-endothelial adhesion molecules[J].Blood,1994,84(7):2068-2101.
[16]Wakefield TW,Strieter RM,Monreal L,et al.Venous thrombosis associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules[J].Arterioscle Thromb Vasc Biol,1995,15(2):258-268.
[17]Baggiolini M,Dewald B,Moser B.Interleukin-8 and related chemotactic cytokines CXC and CC chemokines[J].Adv Immunol.1994,55:97-179.
[18]Downing LJ,Wakefield TW,Strieter RM,et al.Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis[J].J Vasc Surg,1997,25(5):816-827.
[19]李家增,贺石林.血栓形成与临床医学[M].长沙:湖南科学技术出版社,1991.
[20]李仪奎,姜名瑛.中药药理学[M].北京:中国中医药出版社,1992,48-144.
[21]郁琴,宋后燕.水蛭素在深静脉血栓治疗中的作用[J].中国心血管病研究杂志,2005,3(5):392-394.
[22]潘丽华.生三七粉降低血浆凝血固子[J].中国新药与临床杂志,2000,19(4):331-332.
[23]付伟.大剂量黄芪注射治疗糖尿病肾病性肾功能衰竭的临床观察[J].中国中医药信息杂志,2000,11(7):57.
[24]林爱华,李予蓉.黄芪对小鼠免疫功能的影响[J].第四军医大学学报,2003,24(8):2.
[1]Kakkar VV.Pathophysiologic characteristics of venous thrombosis[J].Am J Surg 1985,50(4A):1-6.
[2]Comerota AJ,Stewart GJ,White JV.Combined dihydroergotamine and heparin prophylaxis of postoperative deep vein thrombosis:proposed mechanism of action[J].Am J Surg.1985,150(4A):39-44.
[3]张延龄.静脉血栓形成的防治近况[J].国外医学外科学分册,1991,(2):70.
[4]Dahlback B.Inherited Thrombophilia:resistance to activated protein C as a pathogenic factor of venous thromboembolism[J].Blood,1985,85:607.
[5]Dahlbaek B,Hildebrand B.Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a poperty of factor Ⅴ[J].proc Natl Acad Sci USA,1994,91:1396.
[6]Bertina RM,Koeleman BPC,Koster T,et al.Mutation in blood coagulation factor Ⅴ associated with resisance to activated protein C[J].Nature,1994,369:64.
[7]Voorbeg J,Roclse J,Koopman R,et al.Association of idiopathic thromboembolism with single point-mutation at Agr 506 of factor Ⅴ[J].Lancet,1994,343:1535.
[8]王钦红.抗活化蛋白C是引起静脉血栓形成的一个重要原因[J].中华血液学杂志,1996,(9):499.
[9]储海燕,诸江,王鸿利,等.上海地区深静脉血栓形成患者抗活化蛋白C及FV Leiden突变的初 步调查[J].中华血液学杂志,1996,(9):462.
[10]Sevitts,Grllaghcr N:Venous thrombosis and pulmonary embolism:A clinico-pathological study in injured and burned victims.Br J Surg 1961,48:475.
[11]Thomas DP,Merton RE,Wood RD,et al.The relationship between vessel wall injury and venous thrombosis:an experimential study.Br Haematol 1985,59(3):449.
[12]Robert B.Rutherford,M.D.Rutherford Vascular Surgery(fifth edition)[M]影印版.北京:人民卫生出版社,2002,1920 58.
[13]冯友贤.血管外科学[M].第二版.上海:上海科学技术出版社,1992,195-533.
[14]Carter Cb,Anderson FA,Wheeler HB:Epidemiology and patholphysiology of venous thromboembolism.In Hull RD,Raskob GE,Pinco GF(cds):Venous Thromboembolism:An Evidence-based Atlas.Armonk,NY,Futura Publishing Company,1996,p3.
[15]Luscher TB,Barton M.Biology of the endothelium[J].Clin Cardiol,1997,20(suppl Ⅰ):Ⅱ3-10.
[16]Celermajer DS.Endothelial dysfunction:Do it matters? Is it reversible?[J]J Am Cardiol 1997,30:325-333.
[17]Hunt BJ,Jurd KM.Endothelial cell activation:a central pathophysiologica process[J].B M J,1998,316:1328-1329.
[18]Adams DH,Shaw S.Leucocyte-endothelial interactions and regulation of leucocyte migrati -on[J].Lancet 1994;343:831-6.
[19]Bach FH,Robson SC,Winkler H,et al.Barriers to xenotransplantation[J].Nature Medicine 1995,1:869-73.
[20]张卉,贺蓉,贺石林.炎症与血栓形成[J].中华医学杂志,2004,84(9):784.
[21]Weksler BB,Ley CW,Jaffe EA.Stimulation of endothelial cell prostacyclin production by thrombin,trypsin and the ionophore A23187[J].J Clin Invest,1978,62(5):923-930.
[22]Prescott SM,Zimmerman GA,McIntyre IM.Human endothelial cells in culture produce platelet activating factor(1-alkyl-2-acetyl-sn-60 glycero-3-phosphocholine) when stimulated with thrombin[J].Proc Natl Acad Sci USA,1984,81(11):3534-3538.
[23]Lorant DE,Patel KDA,Mclntyre TM,et al.Coexpression of GMP-140 and platelet activating factor by endothelium stimulated by histamine and thrombin:A juxtacrine system for adhesion and activation of neurophils[J].J Cell Biol,1991,115(1):223-231.
[24]Carlos TM,Harlan JM.Leukocyte-endothelial adhesion molecules[J].Blood,1994,84(7):2068-2101.
[25]Wakefield TW,Strieter RM,Monreal L,et al.Venous thrombosis associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules[J].Arterioscle Thromb Vasc Biol,1995,15(2):258-268.
[26]Baggiolini M,Dewald B,Moser B.Interleukin-8 and related chemotactic cytokines CXC and CC chemokines[J].Adv Immunol.1994,55:97-179.
[27]Downing LJ,Wakefield TW,Strieter RM,et al.Anti-P-selectin antibody decreases inflamm -ation and thrombus formation in venous thrombosis[J].J Vasc Surg,1997,25(5):816-827.
[28]刘政,侯玉芬,周涛,林海青,等.消栓通脉颗粒剂对深静脉血栓形成模型大鼠血浆t-PA、PAI的影响[J].中医药学刊,第24卷第10期2006,24(10):1846-1848.
[29]Rice GE,Munro JM,Bevilacqua MP.Inducible cell adhesion molecule 110(ICAM-1)is an endothelial receptor for lymphocytes A CD11/CD18-independent adhesion mechanism.ExpMed,1990,171(4):1369.
[30]梁春,吴宗贵,仲人前,等.普伐他汀抑制ox-LDL诱导的人外周血单核细胞CD11b表达及与内皮的粘附.中国药理学通报,1999,15(3):249.
[31]Albelds SM,Smith CM,Ward PA,et al.Adhesionmolecules and inflammatory injury[J].FASEB J,1994,8(2):504-512.
[32]宋晓燕.流动剪切力对鼠脑微血管内皮细胞ICAM-1表达的影响[J].生理学报,2001,53(1):13.
[33]卿晨,丁健.黏附分子ICAM-1表达家族在调节细胞凋亡中的作用[J].国外医学·分子生物学分册,2000,22(1):17.
[34]Smith MD,Slavotinek J,Au V,et al.Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression.Rheumatology,2001,40:965-977.
[35]顾光,陈海英,魏平,等.CD54与强直性脊柱炎相关性的临床研究[J].河北医药,2005,27(10):729-730.
[36]邓耀祖,曲伸.医学分子细胞生物学[M].北京:科学出版社,2002;494.
[37]朱彪,薛张纲,蒋豪.粘附分子和心肌缺血再灌注损伤的新进展[J].国外医学·麻醉血与复苏分册,2003;24(3):167-170.
[38]张轶,刘中民.细胞间粘附分子-1与心肌缺血再灌注损伤的关系[J].国外医学·心血管分册,2001;28(5):259-261.
[39]王洪超,周童亮,阎景波,等.内皮细胞缺血再灌注损伤中粒细胞和ICAM-1作用的实验研究[J].中日友好医院学报,2002;16(1):24-27.
[40]郑立新,周晓红,安琪等.PDTC对缺氧/再给氧时血管内皮细胞ICAM-1,VCAM-1表达的作用[J].中国胸心血管外科临床杂志,2004;n(1):53-55.
[41]李家增,贺石林.血栓形成与临床医学[M].长沙:湖南科学技术出版社,1991.
[42]李仪奎,姜名瑛.中药药理学[M].北京:中国中医药出版社,1992,48-144.
[43]张旭,张超英,王文,等.丹参药物血清对HUVEC黏附分子表达及胞内Ca~(2+)的影响[J].南京中医药大学学报,2007,23(1):30-32.
[44]平井爱山.活血化瘀药牡丹皮及其有效成分对芍药酚对血小板的抑制作用及其机理[J].国外医学中医中药分册,1984;(1):53.
[45]李学林,李威,陈国华,等.牛膝活血作用的实验研究[J].中医研究,1990;3(2):27-29.
[46]陈学东,田道法,刘红萍,等.地龙煎液对人出血、凝血时间的影响[J].湖南中学院学报,2003,23(2):10-11.
[47]马恩龙,李艳春,曹颖林,等·溶栓1号抗血小板聚集及抗血栓形成作用[J]·沈阳药科大学学报,2001,18(5):370-372.
[48]马培志,邵凤民.蚯蚓提取物对原发性肾病综合症患者凝血系统的影响[J].中国中西医结合肾病杂志,2002,3(9):528-529.
[49]韩正雪,赖光强,张维,等.地龙水煎剂对血小板聚集的影响[J].中外健康文摘·临床医药版.2008,5(4):25-26.
[50]王秀华,刘爱东,徐彩云.鸡血藤抗血栓形成作用的研究,长春中医学院学报,2005,12(4):41.
[51]陈少鹏,韩雅莉,郭桅,等.少棘蜈蚣纤溶活性蛋白的抗血栓作用[J].中药药理学通报,2007,23(8):1088.
[52]石宏志,高南南,李勇枝,等.泽兰有效部分对血小板聚集和血栓形成的影响[J].中草药.2003,34(10):923-926
[53]Shi H Z,Gao N N,Li Y Z,et al.Effects of active fractions from Lycopus lucidusL.F04 on erythrocyterheology[J].Space Med Med Eng(航天医学与医学工程),2002,15(5):331-334.
[54]陶晋舆,吕环,张秋菊,等.泽泻抗动脉粥样硬化作用系列研究(二)[J].北京中医学院学报,1991,14(6):51.
[55]刘崇铭,王敏,梁力春.淫羊藿黄酮对脑血流和脑缺血的作用[J].沈阳药科大学学报,1995.12(3):192-194.
[56]常德有,董福慧.骨碎补的研究概况[J].吉林中医药,2006,26(6):61-62.
[57]中华人民共和国卫生部药典委员会.中华人民共和国药典(一部)[M].北京:人民卫生出版社,1995:284.
[58]江苏新医学院.中药大辞典(下册)[M],上海:上海科学技术出版社,1997:2243.
[59]王树梓,边全禄.鹿蹄草扩张血管作用的实验研究[J].陕西中医.1989,10(10):473.
[60]郑振源,周述芳,郭敏,等.鹿蹄草对小鼠组织血流量与血浆环核昔酸含量的影响[J].中药通报,1956;11(3):52-52.
[61]庄斐尔.鹿蹄草对心肌营养性血流的影响[J].中药通报,1987;6(6):31.
[62]陈长勋.中药药理学[M].上海科学技术出版社,2006,165.
[63]Marcel Levi,Janine D?rffler-Melly,Gerhard J.Johnson,et al.Usefulness and Limitations of Animal Models of Venous Thrombosis[J].Thromb Haemost,2001,86:1331
[64]Reyers I,Mussoni L,Donati MB,et al.Failure of aspirin at different doses to modify experimental thrombosis in rats[J].Thromb Res,1980,18(5):669.
[65]Myers DD,Hawley AE,Farris DM,et al.P-selectin and leukocyte microparticles are associated with venous thrombogenesis[J].J Vasc Surg 2003,38:1075.
[66]王敏,王骏,邵明远,等.链霉菌产生的新型纤溶酶的纤溶性质和溶栓作用[J].药学学报,1998, 33(7):481.
[67]刘广芬,王晴川,许云禄.蕲蛇酶对动物实验性血栓的防栓和溶栓作用[J].蛇志,1997,9(3):2.
[68]何晓凡,熊石龙,刘发益,等.国产抗凝血酶Ⅲ对实验性静脉血栓形成的预防作用观察[J].血栓与止血,2002,8(1):5
[69]Rhodes JM,Cho JS,Gloviczki P,et al.Thrombolysis for experimental deep venous thrombosis maintain valvular competence and vasoreactivity[J].J Vasc Surg,2000,31:1193.
[70]戎建杰,伍波,何礼荣,等.导管直接溶栓治疗犬股静脉急性深静脉血栓后静脉壁形态学的变化[J].苏州大学学报(医学版),2004,24(2):169.
[71]王辉,王岭,陈江浩,等.腔内超声溶栓治疗犬外周血管血栓形成[J].第四军医大学学报,2003,24(10):870.
[72]周为民,李晓强,余朝文,等.血栓消融、溶栓和取栓对犬股静脉壁形态学影响的研究[J].中国普通外科杂志,2003,18(4):214.
[73]李晓强,杨明,余朝文,等.尿激酶对兔急性血栓后静脉壁形态变化的影响[J].中华医学杂志,2002,82(8):568
[74]季顺东,刘晓健,张荣军,等.99Tcm-抗血栓成分单克隆抗体对动物血栓的放免显像研究[J].苏州医学院报,2000,20(1):4
[75]安锐,张凯军,黄韬,等.99Tcm-SZ-51用于犬静脉血栓模型放射免疫显像的研究[J].临床心血管病杂志,2000,16(12):554
[76]Knight LC,Maurer Ah,Ammar I A,et al.Tc-99m antifibrin fragment for imaging venous thrombi:Evaluation in a canine model[J].Radiology,1989,173:163
[77]杨军,屈立志,杨霄,等.复方丹参片片对深静脉血栓形成纤溶功能的实验观察[J].中药新药与临床药理,2003,14(1):32
[78]豀忠人.激素剂的致瘀血作用和桂枝茯苓丸的祛瘀血作用[J].国外医学·中医中药分册,1985,7(6):4.
[79]覃建民,李增晞,石山.实验性体内血栓形成测定仪的研制和使用[J].中国药理学通报,1992,8(2):236.
[80]王健.静脉血栓形成动物模型的病理学研究[J].蚌埠医学院学报,2003,28(1):7.
[81]李晓强,余朝文,杨明,等.顺行和逆行取栓对静脉瓣膜及血管壁的影响[J].蚌埠医学院学报,2000,25(5):313.
[82]徐晖,朱妙章,裴建民,等.大鼠实验性血栓模型的建立及其评价[J]中国应用生理学杂志,1997,13(1):89-90.
[83]胡敏,赵宏斌,王兵,等.创伤后兔肢体深静脉血栓形成的影响因素[J].中国临床康复,2005,9(10):156-157.
[84]刘涛,卞慧敏,张蕊,等.改良三甲散活血化淤作用实验研究[J].实用中医药杂志,2003,19(10):508-509.
[85]邓祖跃,辛艳飞.番茄红素对高脂血症大鼠血凝及纤溶的影响[J].时珍国医国药,2007,18(1):88-89.
[86]李建林.纤溶系统与动脉血栓形成[J].中西医结合心脑血管病杂志,2006,4(12):1086-1087.
[87]刘伟,王洋,脉通胶囊对大鼠纤溶系统的影响[J].中医药学报,2005,33(2):31-32.
[88]王翠梅,曹红.冠状内皮细胞与心肌缺血再灌注损伤[J].国外医学.麻醉学与复苏分册,2004;25(2):114-117.
[1]Andrew DB,Gregory YHL.Venous thromboembolism.BMJ,2006,332:215-219.
[2]张伯根.下肢深静脉血栓形成治疗的几个问题[J].中华普通外科杂志,2006,21(2):81-83.
[3]Thomas WW,Robert MS,Carol AW,et al.Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules[J].Arteriosclerosis,Thrombosis,and Vascular Biology,1995,15:258-268.
[4]预防骨科大手术后深静脉血栓形成的专家建议-深静脉血栓形成预防座谈会纪要.中华骨科杂志,2005,25(10):636-640.
[5]Frits RR.Venous thrombosis:the role of genes,environment,and behavior[J].Hematology Am Soe Hematol Edue Program,2005:1-12.
[6]Colwell CW Jr,Hardwick ME.Natural History of Venous Thromboembolism.Techniques in Orthopaedics,2004,19:236-239.
[7]Geerts WH,Heit JA,Clagett GP,et al.Prevention of venous thromboembolism.Chest,2001,119:132S-175S.
[8]张强.外科手术后下肢深静脉血栓的预防与治疗[J].中国实用外科杂志,2001,21:263-265.
[9]吕厚山,徐斌.人工关节置换术后下肢深静脉血栓形成[J].中华骨科杂志,1999,19:155-160.
[10]Clagett GP,Anderson FA Jr,Geerts W,et al.Prevention of venous thromboembolism Chest.1998,114:531S -560S.
[11]Sharrock NE,Go G,Sculco TP,et al.Changes in circulatory indices of thrombosis and fihrinolysis during total knee arthroplasty performed under tourniquet[J].J Arthroplasty,1995,10:523-528.
[12]Sharrock NE,Go G,Harpel PC,et al.The John Charnley Award.Thrombogenesis during total hip arthroplasty[J].Clin Orthop RelatRes,1995,(319):16-27.
[13]Menzin J.Richner R.Huse D.et al.Prevention of deep vein thrombosis following total hip replacement surgery with enoxaparin versusunfractionated heparin:a pharm acoeconomic evaluation.Ann Pharmacother,1994,28:271-275.
[14]冯会祥.下肢深静脉血栓形成的诊断和治疗进展.医学理论与实践[M],2008,21(5):527-5-29.
[15]Tove yC,W yattS.Diagnosis,investigation,and management of deep vein thrombosis.Br Med J,2003;326:1180-1186.
[16]Yoshizako T,Sagimura K,Kawamitsu H,et al,Two-dimentional time of flight MR venography:assessment with detection of chronic deep venous thrombosis in combination transfer contrast[J].Comput Assisit Tomogr,1996,20(6):957-964.
[17]De Valois JC,vanSechaik CC,Verzijlbergen F,et al.Contrast venography:from gold standard to "golden backup"inclinically suspected deep vein thrombosis.Eur J Radiol,1990;11:131-137.
[18]Yoshida S,Akiba H,Tamakawa M,et al.Spiral CT venography of the lower extremities by injection via an arm vein in patients with leg swelling.Br JRadiol,2001;74:1013-1016.
[19]Fraser DGW,Moody AR,Morgan PS,et al.Diagnosis of lower limb deep venous thrombosis:a prospective blinded study of magnetic resonance direct thrombusi maging.AnnInternMed,2002;136:89-98.
[20]Westrich GH,Farrell C,Bono JV,et al.The incidence of venous thmmboembolism after total hip arthroplasty:a specific hypotensive epidural anesthesia protocol.J Arthroplasty.1999.14:456 -463.
[21]Prins MH,Hirsh J.A comparison of general anesthesia and regional anesthesia as a risk factor for deep venous thrombosis following hip surgery:a critical review.Thromb Haemost,1990,64:497-500.
[22]陈廖斌,顾洁夫,王华,等.足踝主、被动运动对下肢静脉回流的影响.中华骨科杂志,21(3):145-147.
[23]陈东峰,余楠生,卢伟杰,等.低分子肝素联合间歇充气加压预防人工关节置换术后下肢深静脉血栓形成.中华骨科杂志,2006,26(12):823-826.
[24]Silbersack Y,Taute BM,Hein W,et al.Prevention of deep vein thrombosis after total hip and knee replacement:low molecular-weight heparin in combination with intermittent pneumatic compression.J Bone Joint Surg(Br),2004,86:809- 812.
[25]Ryan MG,Westrich GH,Potter HG,et al.Effect of mechanical compressionon the prevalence of proximal deep venous thrombosis asassessed by magnetic resonance venography.J Bone Joint Surg(Am),2002,84:1998- 2004.
[26]杨刚,吕厚山,高健,等.低分子肝素预防人工髋、膝关节置换术后下肢深静脉血栓形成的研究.中华骨科杂志,2000,38(1):25-28.
[27]邱贵兴,杨庆铭,余楠生,等.低分子肝素预防髋、膝关节手术后下肢深静脉血栓形成的多中心研究.中华骨科杂志,2006,26(12):819-822.
[28]Kakkar W,Lawrence D.Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis:A prospective study.Am J Surg,1985,150:54-63.
[1]吕厚山,徐斌.人工关节置换术后下肢深静脉血栓形成[J].中华骨科杂志,1999,19(3):155.
[2]杨刚,吕厚山,高健,等.低分子肝素预防人工髋、膝关节置换术后下肢深静脉血栓形成的研究[J].中华外科杂志,2000,38(1):25-27.
[3]Brenkel J,Cook RE.Thromboprophylaxis in patients undergoing total hip replacement[J].Hosp Med,2003,64:281-287.
[4]Rmaswami G,Nicolaides AN.The cost- effectiveness of mechanical froms of DVT prophylax is in general surgery[J].Inter Angiol,1996,15(Supp1):21.
[5]Pitto RP,Hamer H,Fabiani R,et al Prophylaxis against fat and bone-marrow embolism during total hip arthroplasty reduces the incidence of postoperative deep vein thrombosis:a controlled,randomized clinical tria[J].J Bone Joint Surg Am,2002,84:39-48.
[6]李伟.髋关节置换术后深静脉血栓形成的中药防治[J].中国中医骨伤科杂志,1998,6(6):36-37.
[7]杨剑.活血利湿法治疗下肢深静脉血栓48例[J].中国现代医药杂志,2005,7(1):9.
[8]黄贵熙.中西医结合治疗下肢深静脉血栓形成31例[J].广西中医药,2003,26(2):29.
[9]高怀林.中西医结合治疗深静脉血栓形成临证探要[J].中医药学刊,2001,19(2):179.
[10]刘明伟,黄海滨,廖小波.活血化瘀方防治髋部骨折术后深静脉血栓[J].山东中医杂志,2002,21(182):722-723.
[11]李萍.奚九一教授治疗血栓性深静脉炎的经验介绍[J].贵阳中医学院学报,1999,21(1):14-16.
[12]朱之升,陈碧岚.中西医结合治疗髋部术后静脉血栓形成[J].浙江中西医结合杂志,2004,14(5):298-299.
[13]姜晓锐,陈联源.消肿活血汤配合低分子肝素钠预防髋部术后深静脉血栓形成65例[J].福建中医药,2006,37(5):27-28.
[14]袁临益,王文斌,冯米敬,等.丹参注射液预防下肢深静脉血栓形成临床观察[J].中医正骨,2006,18(4):6-8.
[15]梅汉尧,周永顶,索鹏,等.丹参预防人工全髋关节置换术后下肢深静脉血栓形成的研究[J].中国中医骨伤科杂志,2006,14(3):14-15.
[16]刘军,万豫尧,许树柴,等.益气活血法预防老年患者髋部术后下肢深静脉血栓形成[J].中国骨伤,2006,19(6):344-347.
[17]李文若,王海彬.川芎嗪、血液循环泵预防全髋置换术后深静脉血栓形成50例[J].新中医,2006,38(4):73.
[18]李玉吉,赵健雄.川芎嗪预防全髋关节置换术后深静脉血栓的疗效观察[J].甘肃中医,2006,19(5):19-20.
[19]饶耀剑,张俊,石福明,等.中药黄芪对全髋术后血液流变学影响[J].中医正骨,2007,19(10):4.
[20]赵代杰,曹飞.疏血通注射液预防下肢人工关节置换术后深静脉栓塞的应用[J].中国社区医师,2008,10(2):56.
[21]胡军林,冯国璋,戴号,等.中西医结合预防全膝关节置换术后深静脉栓塞[J].实用中西医结合临床,2004,4(5):30-31.
[22]沈计荣,蔡文辉,陈茂义,等.自拟活血化瘀汤防治人工膝关节术后深静脉血栓[J].黑龙江中医药.2002,6(6):17-18.
[23]沈映君.中药药理学[M].上海:上海科学技术出版社,1997.136.
[24]刘迅,童培建,章建华.活血通脉汤防治全膝关节置换术后深静脉血栓33例[J].浙江中医药大学学报.2006,30(5):495-496.
[25]闵文,沈计荣,闵正,等.活血Ⅰ号方预防人工髋、膝关节置换术后DVT发生的临床观察[J].中国中医骨伤科杂志,2007,15(12):25-27.
[26]刘光旺,陈茂义,周临东,等.化瘀消肿汤预防髋膝关节置换术后下肢深静脉血栓形成[J].国医论坛,2004,19(4):22.
[27]阮洪江,张世华.活血复元汤配合低分于肝素钠预防人工髋关节置换术后下肢深静脉血栓形成[J].中国骨伤,2005,18(12):719-721.
[28]罗剑虹,方明智,杨静.中西医结合预防髋部骨折术后深静脉血栓形成54例[J].江西中医药,2007,38(10):51.
[29]郁琴,宋后燕.水蛭素在深静脉血栓治疗中的作用[J].中国心血管病研究杂志,2005,3(5):392-394.
[30]潘丽华.生三七粉降低血浆凝血固子[J].中国新药与临床杂志,2000,19(4):331-332.
[31]付伟.大剂量黄芪注射治疗糖尿病肾病性肾功能衰竭的临床观察[J].中国中医药信息杂志,2000,11(7):57.
[32]林爱华,李予蓉.黄芪对小鼠免疫功能的影响[J].第四军医大学学报,2003,24(8):2.
[33]杨刚,吕厚山,高健,等.低分子肝素预防人工髋、膝关节置换术后下肢深静脉血栓形成的研究[J].中华外科杂志,2000,37(1):25-27.